Pharbil Waltrop Gmbh – FDA 483, Feb 14, 2020
An FDA inspection of Pharbil Waltrop Gmbh in Waltrop, Germany, revealed significant deficiencies in manufacturing process controls. The firm failed to establish adequate control procedures for monitoring manufacturing processes, including insufficient drug product sampling plans and uncontrolled labels for samples. Additionally, the company did not determine actual or theoretical yields at the conclusion of manufacturing phases, hindering the recognition and investigation of production deviations.
ID · 6e22f962-0a56-4158-b4f6-d3f0b959c62a
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.